Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Change in Acquisitions & Divestments (2022 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Change in Acquisitions & Divestments for 4 consecutive years, with $2.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Acquisitions & Divestments fell 86.86% to $2.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $33.4 million, a 51.16% decrease, with the full-year FY2024 number at $63.3 million, down 58.23% from a year prior.
  • Change in Acquisitions & Divestments was $2.0 million for Q3 2025 at Whitehawk Therapeutics, down from $3.4 million in the prior quarter.
  • In the past five years, Change in Acquisitions & Divestments ranged from a high of $51.2 million in Q2 2023 to a low of $2.0 million in Q3 2025.
  • A 4-year average of $20.6 million and a median of $15.5 million in 2024 define the central range for Change in Acquisitions & Divestments.
  • Peak YoY movement for Change in Acquisitions & Divestments: skyrocketed 44.02% in 2023, then crashed 86.86% in 2025.
  • Whitehawk Therapeutics' Change in Acquisitions & Divestments stood at $12.8 million in 2022, then surged by 44.02% to $18.4 million in 2023, then decreased by 27.47% to $13.3 million in 2024, then tumbled by 85.0% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for WHWK's Change in Acquisitions & Divestments are $2.0 million (Q3 2025), $3.4 million (Q2 2025), and $14.7 million (Q1 2025).